Investment16 Mar 2026, 09:10 pm
Zydus Lifesciences Subsidiary Sentynl Therapeutics to Acquire Full Rights to Progerinin for Hutchinson-Gilford Progeria Syndrome Treatment
AI Summary
Sentynl Therapeutics, a subsidiary of Zydus Lifesciences Limited, has entered into an agreement with PRG S&T to license the investigational molecule Progerinin (SLC-D011) for Hutchinson-Gilford Progeria Syndrome (HGPS). Upon meeting certain milestones, Sentynl will acquire full rights to the molecule for HGPS, making it the company's second therapy intended for the treatment of HGPS. Progerinin is designed to inhibit the interaction and harmful effects of progerin within cells, thereby improving nuclear integrity and reducing cellular damage. The program is currently finalizing a Phase 2A clinical trial, and data are expected before the end of 1H 2026.
Key Highlights
- Sentynl Therapeutics, a subsidiary of Zydus Lifesciences Limited, will acquire full rights to Progerinin (SLC-D011) for Hutchinson-Gilford Progeria Syndrome (HGPS) treatment.
- Progerinin is an investigational, orally active small-molecule drug being developed as a potential treatment for HGPS.
- The acquisition is subject to certain milestones being met, with data expected from a Phase 2A clinical trial before the end of 1H 2026.
- Progerinin is designed to inhibit the interaction and harmful effects of progerin within cells, improving nuclear integrity and reducing cellular damage.
- Zokinvy® (lonafarnib) is currently the only approved treatment for HGPS and certain processing-deficient Progeroid Laminopathies in multiple countries.